EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
Weiya Zhang,M. Doherty,Thomas Bardin,Eliseo Pascual,V. Barskova,P.G. Conaghan,J Gerster,J Jacobs,Burkhard F. Leeb,Frédéric Lioté,Geraldine M. McCarthy,Patrick Netter,George Nuki,Fernando Perez-Ruiz,A Pignone,J. Pimentao,Leonardo Punzi,Edward Roddy,Till Uhlig,Irena Zimmermann-Górska +19 more
TL;DR: 12 key recommendations for management of gout were developed, using a combination of research based evidence and expert consensus, based on a Delphi consensus approach.
read more
Abstract: Objective: To develop evidence based recommendations for the diagnosis of gout. Methods: The multidisciplinary guideline development group comprised 19 rheumatologists and one evidence based medicine expert, representing 13 European countries. Ten key propositions regarding diagnosis were generated using a Delphi consensus approach. Research evidence was searched systematically for each proposition. Wherever possible the sensitivity, specificity, likelihood ratio (LR), and incremental cost-effectiveness ratio were calculated for diagnostic tests. Relative risk and odds ratios were estimated for risk factors and co-morbidities associated with gout. The quality of evidence was categorised according to the evidence hierarchy. The strength of recommendation (SOR) was assessed using the EULAR visual analogue and ordinal scales. Results: 10 key propositions were generated though three Delphi rounds including diagnostic topics in clinical manifestations, urate crystal identification, biochemical tests, radiographs, and risk factors/co-morbidities. Urate crystal identification varies according to symptoms and observer skill but is very likely to be positive in symptomatic gout (LR = 567 (95% confidence interval (CI), 35.5 to 9053)). Classic podagra and presence of tophi have the highest clinical diagnostic value for gout (LR = 30.64 (95% CI, 20.51 to 45.77), and LR = 39.95 (21.06 to 75.79), respectively). Hyperuricaemia is a major risk factor for gout and may be a useful diagnostic marker when defined by the normal range of the local population (LR = 9.74 (7.45 to 12.72)), although some gouty patients may have normal serum uric acid concentrations at the time of investigation. Radiographs have little role in diagnosis, though in late or severe gout radiographic changes of asymmetrical swelling (LR = 4.13 (2.97 to 5.74)) and subcortical cysts without erosion (LR = 6.39 (3.00 to 13.57)) may be useful to differentiate chronic gout from other joint conditions. In addition, risk factors (sex, diuretics, purine-rich foods, alcohol, lead) and co-morbidities (cardiovascular diseases, hypertension, diabetes, obesity, and chronic renal failure) are associated with gout. SOR for each proposition varied according to both the research evidence and expert opinion. Conclusions: 10 key recommendations for diagnosis of gout were developed using a combination of research based evidence and expert consensus. The evidence for diagnostic tests, risk factors, and co-morbidities was evaluated and the strength of recommendation was provided.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Developments in the scientific and clinical understanding of gout.
TL;DR: Advances in the understanding of hyperuricemia and gout provide new therapeutic targets for the future and new insights into the transporters that handle uric acid in the kidney are provided.
Benzbromarone in the treatment of gout.
Valderílio Feijó Azevedo,Igor Age Kos,Ana Beatriz Vargas-Santos,Geraldo da Rocha Castelar Pinheiro,Eduardo dos Santos Paiva +4 more
- 07 Aug 2019
TL;DR: Benzbromarone is a safe and effective molecule for the treatment of gout, however, due to in vitro and in vivo data related to hepatotoxicity, it is prudent to prescribe it with some caution, especially for patients with an already known liver condition.
European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative
Nienke de Graeff,Noortje Groot,Noortje Groot,Paul A. Brogan,Seza Ozen,Tadej Avcin,Brigitte Bader-Meunier,Pavla Dolezalova,Brian M. Feldman,Isabelle Koné-Paut,Pekka Lahdenne,Stephen D. Marks,Liza J McCann,Clarissa Pilkington,Angelo Ravelli,Annet van Royen,Yosef Uziel,Bas Vastert,Nico M Wulffraat,Sylvia Kamphuis,Michael W. Beresford,Michael W. Beresford +21 more
TL;DR: These Single Hub and Access point for paediatric Rheumatology in Europe recommendations were formulated through an evidence-based consensus process to support uniform, high-quality standard of care for children with rare forms of paediatric systemic vasculitis.
Long-term safety of pegloticase in chronic gout refractory to conventional treatment
Michael Becker,Herbert S B Baraf,Robert A. Yood,Aileen Dillon,Janitzia Vázquez-Mellado,Faith D Ottery,Dinesh Khanna,John S. Sundy +7 more
TL;DR: Improvements in clinical status, in the form of flare and tophus reduction initiated during RCT pegloticase treatment in patients maintaining goal range urate-lowering responses were sustained or advanced during up to 2.5 years of additional treatment.
100
Tophus burden reduction with pegloticase: Results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
Herbert S B Baraf,Michael Becker,Sergio R. Gutierrez-Urena,Edward L. Treadwell,Janitzia Vázquez-Mellado,Claudia D. Rehrig,Faith D Ottery,John S. Sundy,Robert A. Yood +8 more
TL;DR: Pegloticase reduced tophus burden in patients with refractory tophaceous gout, especially those achieving sustained urate-lowering efficacy.
References
•Book
Statistical Power Analysis for the Behavioral Sciences
Jacob Cohen
- 01 Dec 1969
TL;DR: The concepts of power analysis are discussed in this paper, where Chi-square Tests for Goodness of Fit and Contingency Tables, t-Test for Means, and Sign Test are used.
124.4K
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials
TL;DR: The revised CONSORT statement is intended to improve the reporting of an RCT, enabling readers to understand a trial's conduct and to assess the validity of its results.
5.2K
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
TL;DR: This report hopes this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.
5.1K
Epidemiologic Research: Principles and Quantitative Methods.
TL;DR: In this article, the authors present an overview of the main issues in epidemiology research and propose a method for controlling extraneous factors in the context of epidemiological studies, using Logistic Regression with Interaction, Effect Modification, and synergy.
3.7K
Related Papers (5)
Dinesh Khanna,John FitzGerald,Puja P. Khanna,Sangmee Bae,Manjit K. Singh,Tuhina Neogi,Michael H. Pillinger,Joan Merill,Susan J. Lee,Shraddha Prakash,Marian Kaldas,Maneesh Gogia,Fernando Perez-Ruiz,William J. Taylor,Frédéric Lioté,Hyon K. Choi,Jasvinder A. Singh,Nicola Dalbeth,Sanford Kaplan,Vandana Dua Niyyar,Danielle Jones,Steven A. Yarows,Blake J. Roessler,Gail S. Kerr,Charles H. King,Gerald Levy,Daniel E. Furst,N. Lawrence Edwards,Brian F. Mandell,H. Ralph Schumacher,Mark L. Robbins,Neil S. Wenger,Robert Terkeltaub +32 more